CEL-SCI (NYSE:CVM) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of CEL-SCI (NYSE:CVM) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

CEL-SCI Price Performance

NYSE CVM opened at $0.60 on Wednesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. CEL-SCI has a 52-week low of $0.54 and a 52-week high of $3.23. The business has a 50 day simple moving average of $0.91 and a 200 day simple moving average of $1.12. The stock has a market cap of $38.02 million, a price-to-earnings ratio of -1.03 and a beta of 0.69.

Hedge Funds Weigh In On CEL-SCI

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tidal Investments LLC bought a new position in shares of CEL-SCI during the 1st quarter worth approximately $27,000. Calton & Associates Inc. bought a new stake in CEL-SCI in the 3rd quarter valued at $50,000. Black Diamond Financial LLC grew its stake in shares of CEL-SCI by 35.8% in the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after acquiring an additional 19,000 shares in the last quarter. Plotkin Financial Advisors LLC acquired a new position in shares of CEL-SCI during the 3rd quarter worth approximately $98,000. Finally, Cutter & CO Brokerage Inc. grew its position in CEL-SCI by 29.4% during the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after buying an additional 24,634 shares in the last quarter. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.